News

Printer Friendly Version View printer-friendly version
<< Back
Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2014 On August 12, 2014

BOULDER, Colo., July 28, 2014  Array BioPharma Inc. (Nasdaq:  ARRY) will report financial results for the fourth quarter and full year of fiscal 2014 and hold a conference call to discuss those results on Tuesday, August 12, 2014.  Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.

Array BioPharma.

Conference Call Information

Date:

Tuesday, August 12, 2014

Time:

9:00 a.m. Eastern Time

Toll-Free:

(800) 708-4540

Toll:

(847) 619-6397

Pass Code:

37609587

Webcast, including Replay and Conference Call Slides: 

http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhome 

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.  Seven Phase 3 studies are in progress, or are planned to begin this year. These programs include the wholly-owned hematology drug, filanesib (ARRY-520) for multiple myeloma and two partnered cancer drugs, selumetinib (AstraZeneca) and binimetinib (MEK162 / Novartis).  For more information on Array, please go to www.arraybiopharma.com.

CONTACT:

Tricia Haugeto


Array BioPharma Inc.


(303) 386-1193


thaugeto@arraybiopharma.com

Logo - http://photos.prnewswire.com/prnh/20121029/LA02195LOGO  

SOURCE Array BioPharma Inc.